The BLOCADE Feasibility Study

Grant number: 1006171 | Funding period: 2011 - 2015

Completed

Abstract

The BLOCADE Feasibility Study aims to find out what is needed for a study to see if the drug carvedilol reduces heart disease events in people who need kidney dialysis. Carvedilol is widely used to treat the types of heart disease that are common in people on dialysis but the nature of dialysis may lead to more side effects or to less benefit. A Feasibility Study must be done first to properly plan a large study of carvedilol in people on dialysis that answers this important question.

Related publications (3)

Carvedilol and cardiac biomarkers in dialysis patients: Secondary analysis of a randomized controlled trial

MA Roberts, D Darssan, SV Badve, RP Carroll, MA Fahim, BA Haluska, CM Hawley, NM Isbel, MR Marshall, EM Pascoe, E Pedagogos, HL Pilmore, P Snelling, T Stanton, KS Tan, AM Tonkin, LA Vergara, FL Ierino

2017-01-01

Background/Aims: Cardiac biomarkers are associated with cardiac abnormalities and adverse outcomes in dialysis patients. Our aim w..

The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) feasibility study: A randomized controlled trial

MA Roberts, HL Pilmore, FL Ierino, SV Badve, A Cass, AX Garg, NM Isbel, H Krum, EM Pascoe, V Perkovic, A Scaria, AM Tonkin, LA Vergara, CM Hawley, A Levin, D Hare, A Martin, DC Wheeler, G Fulcher, H Brown

2016-06-01

Background β-Blocking agents reduce cardiovascular mortality in patients with heart disease, but their potential benefit in dialys..

The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study

MA Roberts, HL Pilmore, FL Ierino, SV Badve, A Cass, AX Garg, CM Hawley, NM Isbel, H Krum, EM Pascoe, AM Tonkin, LA Vergara, V Perkovic

2015-03-01

Aims The Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study aims to determine the feasibility of a l..

University of Melbourne Researchers

Francesco Ierino